New drug shrinks lung tumors before surgery in early trial

NCT ID NCT07428044

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether the drug trastuzumab deruxtecan can shrink tumors in people with a specific type of lung cancer (HER2-amplified or HER2-mutated) before they have surgery. About 14 participants with stage II to IIIB non-small cell lung cancer will receive the drug and then have their tumors removed. The main goal is to see how many people have a major reduction in viable tumor cells after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan (a drug that targets HER2 and delivers chemotherapy directly to cancer cells)
What this could lead to: If successful, this could show that giving trastuzumab deruxtecan before surgery shrinks tumors more effectively, potentially leading to a new treatment option for this type of lung cancer.
What could go wrong: This is a small, early-phase trial with only 14 people, so results may not apply to everyone. The drug can cause side effects like lung inflammation, and it's not yet proven to improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER STAGE II NON-SMALL CELL LUNG CANCER STAGE IIIA NON-SMALL CELL LUNG CANCER STAGE IIIB

Contacts and locations

Locations

Centre Hospitalier de l'Université de Montreal (Data Collection Only)
NOT_YET_RECRUITING

Montreal, Quebec, H2L 4M1, Canada
Mayo Clinic (Data Collection Only)
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
RECRUITING

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States
University of Michigan (Data Collection Only)
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.